Nasal Polyposis Epidemiology Forecast Insight

DelveInsight’s ‘Nasal Polyposis (NP)- Epidemiology Forecast–2030’ report delivers an in-depth understanding of the Nasal Polyposis, historical and forecasted epidemiology as well as the Nasal Polyposis epidemiology trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2018–2030

Nasal Polyposis (NP) Disease Understanding

Nasal polyposis (NP) is small, benign (Noncancerous) drop-like growths appearing in the mucosa (lining tissues) of the nose and may block the nasal passageway. Nasal polyposis tends to be present on both sides of the nasal cavity. Small nasal polyps may not reflect any symptoms, but the larger growths or groups of nasal polyps can block the nasal passages or lead to breathing problems, a lost sense of smell, and frequent infections. One-sided nasal polyps may need to be investigated further as they might be malignant nasal or sinus tumors. Nasal polyps are a subgroup of chronic rhinosinusitis (CRS). CRS is a condition where the nasal cavity and sinuses are inflamed for more than 4 to 12 weeks. Patients suffering from CRS condition can be progressed into chronic rhinosinusitis with nasal polyposis (CRSwNP), and chronic rhinosinusitis without nasal polyposis (CRSsNP). Only a portion of CRS will develop nasal polyposis.

 

CRSwNP is a potentially debilitating condition in adults that are characterized by inflammation of the nose and paranasal sinuses with the presence of nasal polyps. People with a history of chronic sinus infections, allergic rhinitis, asthma, cystic fibrosis, sensitivity to NSAIDs like ibuprofen and aspirin, and Churg–Strauss syndrome are more prone to get NP.

 

Patients suffering from NP may experience chronic nasal congestion, running nose, postnasal drip, reduced sense of smell and taste, difficulty in breathing, pressure in the face or forehead area, snoring, sleep apnea, and others.

 

Nasal Polyposis (NP) Diagnosis

For the diagnosis of nasal polyps, an ENT specialist or any other physician first look into nasal passages with a special lighted instrument known as a nasoscope. The most preferred techniques are confirming the location, size, and severity of polyps nasal endoscopy, and radiological imaging. Further allergy tests and blood tests can be done to determine other disease-related components. 

Continued in the report…..

Nasal Polyposis (NP) Epidemiology Perspective by DelveInsight

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by total prevalent cases of chronic rhinosinusitis (CRS), diagnosed prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of nasal polyposis, and gender-specific diagnosed prevalent cases of nasal polyposis scenario of Nasal Polyposis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom) and Japan from 2018 to 2030.

Nasal Polyposis Detailed Epidemiology Segmentation

  • Total prevalent cases of Chronic Rhinosinusitis in the 7MM were found to be 69,106,578 in 2020, which are expected to increase at a CAGR of 0.52% during the study period.
  • The diagnosed prevalent cases of CRS in the 7MM were found to be 17,801,468 in 2020, which are expected to increase at a CAGR of 0.54% for the study period of 2018-2030.
  • As per DelveInsight’s estimates, 7MM accounts for 4,314,505 diagnosed prevalent cases of nasal polyposis, which are expected to increase at a Compound Annual Growth Rate (CAGR) of 0.56%.
  • Among 7MM, the United States has the highest diagnosed cases of nasal polyposis with 2,158,587 cases in 2020. Among these cases, 55% of cases were males (1,187,223 cases were male in 2020).
  • In EU-5, Germany had the highest diagnosed cases of nasal polyposis with 590,229 cases, followed by France with 429,595 cases and the UK with 422,927 cases, in 2020. While Spain had the least number of cases with 196,396 in 2020.
  • The EU-5 accounts for 1,952,117 diagnosed prevalent cases of nasal polyposis, which is expected to increase by 2030 at a CAGR of 0.22%.
  • In 2018, Japan had 203,801 diagnosed cases of nasal polyposis ranking second-lowest among 7MM. These cases are expected to decrease by 2030 at a CAGR of -0.16% due to decreasing adult population in the country during the forecasted period (2021–2030).

Scope of the Report

  • The report covers the descriptive overview of Nasal Polyposis, explaining its symptoms, etiology, pathogenesis, and various diagnostic approaches.
  • The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
  • The report assesses the disease risk and burden of Nasal Polyposis.
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
  • The report provides the segmentation of the disease epidemiology for 7MM total prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of chronic rhinosinusitis, diagnosed prevalent cases of nasal polyposis, and gender-specific diagnosed prevalent cases of nasal polyposis.

Report Highlights

  • 10-Year Forecast of Nasal Polyposis
  • 7MM Coverage
  • Total Prevalent Cases of Chronic Rhinosinusitis
  • Diagnosed Prevalent Cases of Chronic Rhinosinusitis
  • Diagnosed Prevalent Cases of Nasal Polyposis
  • Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis 

Key Questions Answered

  • What are the disease risk and burdens of Nasal Polyposis (NP)?
  • What is the historical Nasal Polyposis (NP) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK), and Japan?
  • What would be the forecasted patient pool of Nasal Polyposis (NP) at the 7MM level?
  • What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Nasal Polyposis (NP)?
  • Out of the above-mentioned countries, which country would have the highest patient population of Nasal Polyposis (NP) during the forecast period (2021–2030)?
  • At what CAGR the population is expected to grow across the 7MM during the forecast period (2021–2030)?

Reasons to buy

The Nasal Polyposis (NP) report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the 7MM Nasal Polyposis (NP) epidemiology forecast.
  • The Nasal Polyposis (NP) epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
  • The Nasal Polyposis (NP) epidemiology model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the 10-year forecast period using reputable sources.

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

1. Key Insights

2. Report Introduction

3. Nasal Polyposis Epidemiology Overview at a Glance

  • 3.1. Patient Share (%) Distribution of Nasal Polyposis  in 2018
  • 3.2. Patient Share (%) Distribution of Nasal Polyposis in 2030

4. Executive Summary of Nasal Polyposis

5. Disease Background and Overview: Nasal Polyposis

5.1. Introduction

5.2. Signs and Symptoms

5.3. Etiology

5.4. Causes

5.5. Pathogenesis

5.6. Diagnostic Approach

5.6.1. JESREC Score Criteria for the Diagnosis of Eosinophilic Chronic Rhinosinusitis

5.6.2. Diagnostic Algorithm

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. Methodology of Epidemiology

6.3. Assumptions and Rationale: 7MM

6.3.1. The United States

6.3.2. Five Major European Countries (Germany, France, Italy, Spain, and the United Kingdom)

6.3.3. Japan

6.4. Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the 7MM

6.5. Total Diagnosed Prevalent Cases of Nasal Polyposis in the 7MM

6.6. The United States

6.6.1. Prevalent Cases of Chronic Rhinosinusitis in the United States

6.6.2. Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the United States

6.6.3. Diagnosed Prevalent Cases of Nasal Polyposis in the United States

6.6.4. Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the United States

6.7. EU-5

6.7.1. Prevalent Cases of Chronic Rhinosinusitis in the EU-5

6.7.2. Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the EU-5

6.7.3. Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5

6.7.4. Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5

6.8. Japan

6.8.1. Prevalent Cases of Chronic Rhinosinusitis in Japan

6.8.2. Diagnosed Prevalent Cases of Chronic Rhinosinusitis in Japan

6.8.3. Diagnosed Prevalent Cases of Nasal Polyposis in Japan

6.8.4. Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in Japan

7. Patient Journey

8. KOL Views

8.1. United States

8.2. EU-5

8.3. Japan

9. Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Table

Table 1: Summary of Nasal Polyposis Epidemiology (2018–2030)

Table 2: JESREC score criteria for the diagnosis of eosinophilic chronic rhinosinusitis

Table 3: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the 7MM, in ‘000’ (2018–2030)

Table 4: Total Diagnosed Prevalent Cases of Nasal Polyposis in the 7MM, in ‘000’ (2018–2030)

Table 5: Prevalent Cases of Chronic Rhinosinusitis in the United States, in ‘000’ (2018–2030)

Table 6: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the US, in ‘000’ (2018–2030)

Table 7: Diagnosed Prevalent Cases of Nasal Polyposis in the US, in ‘000’ (2018–2030)

Table 8: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the US, in ‘000’ (2018–2030)

Table 9: Prevalent Cases of Chronic Rhinosinusitis in the EU-5, in ‘000’ (2018–2030)

Table 10: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the EU-5, in ‘000’ (2018–2030)

Table 11: Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5, in ‘000’ (2018–2030)

Table 12: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5, in ‘000’ (2018–2030)

Table 13: Prevalent Cases of Chronic Rhinosinusitis in Japan, in ‘000’ (2018–2030)

Table 14: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in Japan, in ‘000’ (2018–2030)

Table 15: Diagnosed Prevalent Cases of Nasal Polyposis in Japan, in ‘000’ (2018–2030)

Table 16: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in Japan, in ‘000’ (2018–2030)

List of Figures

Figure 1: Nasal polyps in the nose and sinus cavity

Figure 2: Anatomy of normal nasal area vs. Chronic Rhinosinusitis with Nasal Polyposis

Figure 3: Radiographic findings in severe Chronic Rhinosinusitis with Nasal Polyposis

Figure 4: Primary symptoms of Nasal polyps

Figure 5: Secondary symptoms of Nasal polyps

Figure 6: Etiology of Nasal Polyps

Figure 7: Causes of Nasal Polyps

Figure 8: Hypothetical timeline and interactions of events in the formation of nasal polyps

Figure 9: Differential diagnosis of nasal polyps

Figure 10: Diagnostic algorithm of refractory chronic rhinosinusitis

Figure 11: Four-step diagnosis of sinonasal disorders

Figure 12: Diagnostic-therapeutic Algorithm in Nasal Polyposis

Figure 13: Prognostic index of nasal polyp relapse based on clinical and cytologic grading

Figure 14: Total Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the 7MM, in ‘000’ (2018–2030)

Figure 15: Total Diagnosed Prevalent Cases of Nasal Polyposis in the 7MM, in ‘000’ (2018–2030)

Figure 16: Prevalent Cases of Chronic Rhinosinusitis in the United States, in ‘000’ (2018–2030)

Figure 17: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the US, in ‘000’ (2018–2030)

Figure 18: Diagnosed Prevalent Cases of Nasal Polyposis in the US, in ‘000’ (2018–2030)

Figure 19: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the US, in ‘000’ (2018–2030)

Figure 20: Prevalent Cases of Chronic Rhinosinusitis in the EU-5, in ‘000’ (2018–2030)

Figure 21: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in the EU-5, in ‘000’ (2018–2030)

Figure 22: Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5, in ‘000’ (2018–2030)

Figure 23: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in the EU-5, in ‘000’ (2018–2030)

Figure 24: Prevalent Cases of Chronic Rhinosinusitis in Japan, in ‘000’ (2018–2030)

Figure 25: Diagnosed Prevalent Cases of Chronic Rhinosinusitis in Japan, in ‘000’ (2018–2030)

Figure 26: Diagnosed Prevalent Cases of Nasal Polyposis in Japan, in ‘000’ (2018–2030)

Figure 27: Gender-specific Diagnosed Prevalent Cases of Nasal Polyposis in Japan, in ‘000’ (2018–2030)

Figure 28: Patient Journey

Forward to Friend

Need A Quote